Legend Biotech (LEGN) Revenue (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Revenue data on file, last reported at $305.1 million in Q1 2026.

• Quarterly Revenue rose 56.46% year-over-year to $305.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 56.38% YoY) and the FY2025 annual result came in at $1.0 billion, up 64.02% from the prior year.
• Revenue steadied at $305.1 million in Q1 2026, from $306.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $79.5 billion in Q4 2023 to a low of $12.0 million in Q2 2022.
• A 5-year average of $4.8 billion and a median of $160.2 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue jumped 287469.21% — and 2024, when it slumped 99.77%.
• Tracing LEGN's Revenue over 5 years: stood at $27.6 million in 2022, then jumped by 287469.21% to $79.5 billion in 2023, then tumbled by 99.77% to $186.5 million in 2024, then soared by 64.24% to $306.3 million in 2025, then declined by 0.39% to $305.1 million in 2026.
• The last three Revenue figures came in at $305.1 million (Q1 2026), $306.3 million (Q4 2025), and $272.3 million (Q3 2025), per Business Quant data.